Sugi Predict

Sugi Predict / Compounds / SCHEMBL330385

SCHEMBL330385

SCHEMBL330385

CCOC(=O)c1s[c]nc1-c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.59
▸ HSD17B10 Q99714 2/20 0.59
▸ HPGD P15428 2/20 0.56
▸ DHODH Q02127 6/20 0.54
▸ CDC7 O00311 3/20 0.54
▸ DBF4 Q9UBU7 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ TRPM8 Q7Z2W7 1/20 0.53
▸ ADORA3 P0DMS8 2/20 0.51
▸ MAPT P10636 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ GSTO1 P78417 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ RARA P10276 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8810138 0.83 TRPM8 (0.50) ALDH1A1HSD17B10HPGDMEN1KMT2A
SCHEMBL330380 0.78 SMN1; SMN2 (0.46) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL330990 0.78 HPGD (0.55) ALDH1A1HPGDMEN1KMT2ACYP1A2
SCHEMBL3277191 0.77 KDM4E (0.46) ALDH1A1HPGDDHODHCDC7DBF4
SCHEMBL3277726 0.77 TRPM8 (0.55) ALDH1A1HSD17B10HPGDMEN1KMT2A
SCHEMBL330020 0.77 ALDH1A1 (0.39) ALDH1A1HSD17B10HPGDCDC7DBF4
SCHEMBL6816550 0.77 ALDH1A1 (0.59) ALDH1A1HSD17B10HPGDDHODHCDC7
SCHEMBL1561223 0.77 ALDH1A1 (0.59) ALDH1A1HSD17B10HPGDDHODHCDC7
SCHEMBL8823153 0.77 ALDH1A1 (0.75) ALDH1A1HSD17B10HPGDDHODHCDC7
SCHEMBL2442977 0.76 LMNA (0.49) ALDH1A1HSD17B10HPGDCDC7DBF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 — — US claimed
US-20080311074-A1 Inhibitors against activation of NF-kappaB INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) 2008-12-18 — — US claimed
US-20080249071-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-10-09 — — US claimed
US-20080234233-A1 MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) 2008-09-25 — — US claimed
EP-1847263-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-24 — — EP claimed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 — — US claimed
EP-1649852-A1 CHROMATOSIS REMEDIES Institute of Medicinal Molecular Design, Inc. (JP) 2006-04-26 — — EP claimed
EP-0343894-B1 BENZAMIDE PROTEASE INHIBITORS PFIZER INC. (US) 1992-06-10 — — EP claimed
US-4948891-A ANTI-PLASMIN AND ANTI-THROMBIN AGENTS PFIZER INC. (US) 1990-08-14 — — US claimed
EP-0343894-A1 Benzamide protease inhibitors PFIZER INC. (US) 1989-11-29 — — EP claimed
JP-2017177-A — — None — — JP disclosed
JP-7242663-A — — None — — JP disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 — — US disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 — — US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 — — US disclosed
US-4948901-A ANTI-PLASMIN AND ANTI-THROMBIN AGENTS PFIZER INC. (US) 1990-08-14 — — US disclosed
US-4948891-A ANTI-PLASMIN AND ANTI-THROMBIN AGENTS PFIZER INC. (US) 1990-08-14 — — US disclosed
JP-H0217177-A BENZAMIDE TYPE PROTEASE INHIBITOR PFIZER INC 1990-01-22 — — JP disclosed
EP-0343894-A1 Benzamide protease inhibitors PFIZER INC. (US) 1989-11-29 — — EP disclosed
US-4874864-A ANTIPLASMIN, ANTITHROMBIN AGENTS PFIZER INC. (US) 1989-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311074-A1 Inhibitors against activation of NF-kappaB NFKBIA, IKBKB, RELA ALDH1A1 2096/4885HSD17B10 2440/4885HPGD 240/4885
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A ALDH1A1 479/4885HSD17B10 632/4885HPGD 272/4885
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A ALDH1A1 563/4885HSD17B10 601/4885HPGD 238/4885
US-20080249071-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A ALDH1A1 563/4885HSD17B10 601/4885HPGD 238/4885
US-20080234233-A1 MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAPT, TFEB, MAOA ALDH1A1 425/4885HSD17B10 1152/4885HPGD 647/4885
US-20070042997-A1 Medicament for treatment of dermal pigmentation TYR, XDH, XPA ALDH1A1 140/4885HSD17B10 890/4885HPGD 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.